| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,775 |
3,577 |
$173K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
317 |
274 |
$25K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
280 |
264 |
$9K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
64 |
63 |
$4K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
402 |
390 |
$4K |
| 87428 |
|
69 |
69 |
$4K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
264 |
255 |
$4K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
19 |
19 |
$3K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
37 |
37 |
$2K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
13 |
13 |
$997.85 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
12 |
12 |
$928.50 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
12 |
12 |
$928.50 |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
19 |
19 |
$658.33 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
42 |
38 |
$621.84 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
27 |
26 |
$617.34 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
64 |
63 |
$510.40 |
| 81002 |
|
41 |
40 |
$90.79 |